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ABSTRACT
Alzheimer's disease (AD) is the most common neurodegenerative disease, characterized by
progressive amyloid plaque aggregation, neurofibrillary tangles, and cortical tissue death. As
the prevalence of AD is projected to climb in coming years, there is a vested interest in
identifying endophenotypes by which to improve diagnostics and direct clinical
interventions. The risk for complex disorders, such as AD, is influenced by multiple genetic,
environmental, and lifestyle factors. Significant strides have been made in identifying genetic
variants linked to AD through the genome-wide association study (GWAS). It has been
estimated in more recent years, however, that GWAS-identified variants account for limited
AD heritability, suggesting the role of non-sequence genetic mechanisms, such as epigenetic
moderators. By influencing gene expression, epigenetic markers have been linked to ageassociated decline through modulation of chromatin architecture and global genome
instability, though such mechanisms are also involved with a number of normal biological
processes, including neurogenesis. As the strategies of clinical genetics shift to include a
heavier focus on epigenetic contributors, altered adult neurogenesis presents itself as a strong
candidate for an endophenotype of AD development. This thesis proposes that, due to
neuropathological dysfunction of epigenetic mechanisms in AD, new generations of neurons
fail to proliferate, differentiate, and mature correctly, resulting in the larger loss of neurons
and cognitive deficits characteristic to neurodegenerative disease. The plasticity of the
epigenome and the role of epigenetic factors as mediators of the genome and the environment
make such alterations attractive in AD research and implies the potential for therapeutic
interventions. The present review submits neurogenesis as a viable target of epigenetic
research in AD, highlights shared loci between neurogenesis and AD in the epigenome, and
considers the promises and limitations of the neurogenic endophenotype.
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Section I: Introduction
Advancements in technology and healthcare access in the last several decades have
resulted in a continuous increase in life expectancy. Population projections in the United
States show that the number of elderly Americans will rise dramatically through 2050. This
steady march of America’s baby boomers into old age corresponds with an increasing
prevalence of Alzheimer’s disease (AD) and other neurodegenerative disorders and their
accompanying need for the allocation of resources for its patients’ care and treatment.
Research by Bredfeldt et al. (2015) examines the current trajectory and economic impact of
AD, concluding that the prevalence and incidence of the disorder, as well as its long-term
care spending costs, pose a significant obligation to the economy. Their research estimates
that, as the first baby boomers reach their 60s and early 70s, the prevalence of AD in the
United States will be 1.2% in 2020 (Bredfeldt et al., 2015); current estimates suggest that 5.7
million Americans have AD, indicating a national prevalence of 1.75%, already higher than
previous projections for the year 2020. Predictions from Cornuitiu (2015) corroborate these
findings, adding that, by the year 2040, more than twice as many baby boomers will have AD
(10.3 million) compared to those of their equivalent ages in 2015 (4.7 million) (Cornuitiu,
2015). These results are especially disquieting when it must be acknowledged that AD,
dementia, and other age-moderated cognitive impairments are not synonymous. Rather, the
burden of these non-AD disorders is not covered by these estimates, and, therefore,
understates the population that will be affected by neurodegeneration in the coming years.
Neurodegenerative disorders are characterized by progressive neuronal death and
cellular dysfunction; as such, aging constitutes an important risk factor. The most endemic of
these disorders, including AD, Parkinson’s disease (PD), frontotemporal lobar degeneration
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(FTL/D), and amyotrophic lateral sclerosis (ALS), have no effective treatments (Harari &
Cruchaga, 2016). Of the many varieties of neurodegenerative disorders (NDD), marked cell
loss is a trait shared by all, though many also exhibit characteristics of abnormal and
dysfunctional axons, neurites, and a decline in the neurotransmitter network both before and
during neuronal loss. Investigative studies into the causes and underlying mechanisms to
complex neurological disorders are still in their infancy. Barring no treatments to delay onset
or provide a cure, estimates on the incidence of AD and other NDDs are expected to reach
epidemic proportions within the foreseeable future (Allen et al., 2014). Geriatric populations
are already immensely affected by the disease, with nearly one in nine Americans aged 65
and older has AD; however, by the time this population reaches age 85 and older, one in
three (32%) will have AD (Allen et al., 2014). It is the sixth-leading cause of death in the
United States, and the fifth-leading cause of death among those ages 65 and older, behind
heart disease, cancer, chronic obstructive pulmonary disease (COPD), and cerebrovascular
disease or stroke (Hsu & Marshall, 2018). As a cause of death, AD increased significantly
from 1979 to 1988, where it stabilized before gradually increasing again starting in 1992.
Presently, AD is the most common type of age-related neurodegenerative disorder (Allen et
al., 2014). Like many disorders with a neurological component, AD may have experienced
this increase due to improvements in post-mortem diagnosis, facilitation in reporting, and a
wider knowledge of the condition within medical communities (Hoyert, 1996).
According to Allen et al. (2014), there were five FDA-approved drugs for providing
temporary relief of symptoms in some patients later diagnosed with AD. None of these
therapies slowed or halted disease progression, however. In addition, several nonpharmacological therapies have been released, aimed at improving quality of life through
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symptom management. These tactics include physical therapy, reminiscence therapy, and
cognitive stimulations (Allen et al., 2014). The rising epidemic possibility and treatment
futility demonstrate the importance of apprehending neurodegeneration in the coming years.
The National Institute on Aging proposes that precision medicine may be the key to finding
the most effective ways to diagnose, treat, and prevent diseases, such as AD, in an individual.
This approach takes into account personal variability in genes, environment, and lifestyle to
create a more accurate risk assessment and targeted treatment plans for diverse populations.
Multifactorial genetic disorders, such as AD, are likely influenced by multiple genetic
and environmental factors. Critical developments in recent research suggests that some of
these factors influence disease risk through effects on gene expression (Allen et al., 2014).
Rising in popularity and feasibility within complex disease research is the prospect of
epigenetics. Epigenetics is a field of study focused on heritable changes in gene expression
that do not implicate alterations to an individual’s underlying DNA sequence. These
mechanisms translate external experiences into neural signals which launch the production of
gene regulatory elements inside a cell. Gene regulatory proteins attract or repel enzymes that
add or remove epigenetic markers. These markers control protein production by activating or
repressing genes, thereby shaping how organisms function. These changes occur throughout
normal growth and development, bearing crucial involvement in cellular biodiversity and
differentiation; however, they are also linked to more damaging processes, such as tumor
formation. While much of the original investment in epigenetics lay in genetic assimilation
and an organism’s stress response (Waddington, 1942), there has been a renewed interest in
the reversible properties of epigenetic changes and their clinical implications in cancer,
immune disorders, and neuropsychiatric pathologies.
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Many notably heritable diseases, including AD, are moderated by complex
interactions of genetic and environmental factors which shape an individual’s risk
susceptibility. Such environmental factors include diet, physical exercise, exposure to toxic
substances, and viruses, which can not only predispose an individual to a given disorder but
also, if left untreated or unaltered, can induce a chronic inflammatory response (Grant et al.,
2002). Exposure to toxins, such as heavy metals, has been linked to an increase in oxidative
stress in neurons and subsequent cell death and neurodegeneration. While the impact of the
environment on the pathological pathways of disease cannot be ignored in complex diseases,
the interaction of well-replicated susceptibility genes and environmental factors may provide
more empirical information on disease development. There are a great deal of studies,
including many which precede the recent revolution of genomic research; they outline an
etiological perspective on disease risk and progression, highlighting the role of the
environment. These publications interrogate particular risk and protective factors across
populations and geographic regions, through occupational and ecological studies. The
purpose of this research, however is to recognize the underlying susceptibility networks
which predispose an individual to AD and the ways in which developing epigenetic research
can inform an improved endophenotype for this neurodegenerative disease.
While epigenetic research grows, so, too, does the urgency for a reliable
endophenotype by which to diagnose and treat the complex disorders these changes
moderate. Post mortem hallmarks are unaccommodating to diseases which progress in vivo,
and their use poorly reflects the innovation and development of newer imaging and
sequencing technologies. As a result, neuroscientists and clinicians alike seek a new
biomarker for AD, one which might be detectable prior to a patient’s death and, ideally,
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whose development begins prior to cognitive deficits. In recent years, neurogenesis has
become a popular candidate for this endophenotype (Horgusluoglu et al., 2016), as its
dysfunction within the adult brain would reflect a considerable overlap with the cognitive
deficits linked to neurodegenerative disorders. During development, the structure of the
nervous system is established through the precise and ordered production of neurons. In
many regions of the brain, new neurons do not form after early development; however, in the
dentate gyrus and in the olfactory bulb, the production of new neurons, or neurogenesis,
occurs throughout life (Lledo et al., 2006), though the causes are not entirely clear.
Neurodegeneration was described previously as a process of orchestrated cell death in a
disease case. To fully encapsulate neurodegenerative disorders, however, it must be
considered that neurons are not only dying at abnormal levels but that they also may not be
produced correctly or may not migrate at the same quality and pace of non-diseased neurons.
In recent years, neurogenesis has asserted itself within a growing clinical interest (Fig. 1).
Publication data from the last several decades demonstrates the immense attention paid to
AD and epigenetics and the early signs of neurogenesis invocation in these journals.
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Figure 1. The increase in usage for “Alzheimer’s,” “Epigenetic*,” “Neurogenesis,” and
“GWAS” in PubMed publication titles and abstracts since 1960, using data compiled on
October 1, 2018. This data uses the number of publications as a proxy for growing scientific
investment in the neurogenetic field and applies it to Alzheimer’s disease.
Recent publications have shown a vested interest in AD and a growing presence of
epigenetics in clinical research. The integration of epigenetic perspectives in understanding
AD is reflected in the growing overlap between “Alzheimer’s” and “Epigenetic*” in PubMed
publications (Fig. 2). As imaging technologies and sequencing arrays improve, neurogenesis
continues to gain traction within larger spheres; for example, immunohistochemistry within
human brain tissue samples has been used to link neurogenic processes with pre-existing
neural networks (Li et al., 2008).
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Figure 2. The intersection of
“Epigenetic*”, “Neurogenesis”,
and “Alzheimer’s” in number hits
within titles and abstracts of
PubMed articles, using data
compiled on October 1, 2018.
These publications advance
knowledge and strategies which
promise to yield a more
interdisciplinary approach to
understanding diseases.

This thesis seeks to steer the course of genetic and epigenetic research into the
etiology of AD towards neurogenesis, a still not entirely understood biological process of cell
growth and development in the nervous system. It aims to answer the questions as to whether
AD and other neurodegenerative disorders are a product of cell death alone, or, as more
recent research would suggest, the result of neuron death as well as a dysfunction in
replacing and regenerating synapses. Recent research has indicated that neurogenic processes
are under extensive epigenetic control and are subject to alteration through environmental
factors, such as physical exercise and enriched environment (Yao & Jin, 2014). Furthermore,
in the years to come, it will be imperative to understand and distinguish healthy from
disordered aging, especially as it pertains to cognitive decline and deficits in learning and
memory. Through an analysis of these increasingly intersecting fields, I hope to contribute to
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a newer strategy of unraveling complex disease etiology by looking for patterns of gene
expression and relating them to patterns of the neural landscape seen in disease cases. The
coming years represent an important inflection point within neurogenetics, in which the field
of epigenetics must turn a corner to best address the growing incidence of AD.

ENDOPHENOTYPE FOR ALZHEIMER’S DISEASE

13

Section II: The Model System for Neuropsychiatric Genetic Research
Though it has been over a century since the first description of AD, in a 1906
publication by Alois Alzheimer, the German psychiatrist and pathologist who would lend the
disease his name, our capacity for diagnosing and treating the disease has improved little.
The Alzheimer’s Association identifies three general stages of AD progression: mild AD, or
early stage; moderate AD, or middle stage; and severe AD, or late stage. Early symptoms
include a decreased ability to focus and reason and a loss of memory, but later stages of the
disease are characterized by greater cognitive decline, mood instabilities, and abnormalities
in coordinated movement (Donovan et al., 2014). Neurological changes related to the
progression of AD begin years before symptoms of the disease can be recognized; this period
of preclinical development can last for years. An individual’s risk of acquiring AD is
influenced by complex interactions between genetic risk susceptibility, epigenetic
modifications, and environmental risk factors (Gangisetty, 2018).
Two major hallmarks of AD pathology that have arisen in the last decade are the
accumulation of amyloid-β plaques and tangles of intracellular hyperphosphorylated tau
protein. It is thought that the abnormal cleavage of the amyloid precursor protein (APP) leads
to an excess of amyloid-β peptide accumulation, in accordance with the “amyloid cascade”
hypothesis (Hardy & Higgins, 1992). These peptides form oligomer aggregates within
extracellular neuronal synapses. This protein is not unique to humans, but, rather, it is largely
conserved throughout many species, from Drosophila to humans (Cassar & Kretzschmar,
2016). However, this specific cleavage of APP produces toxic intermediate protein
aggregates, containing an insoluble form of amyloid-β (Allen et al., 2014; Gangisetty, 2018).
Amyloid-β has been linked to mitochondrial dysfunction, inflammation, and synaptotoxicity
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(Selko, 2002). When tau, a microtubule-associated protein (MAP), becomes
hyperphosphorylated in neurons, it prefers itself to the cytoskeletal element. The result is an
intraneuronal neurofibrillary tangle (Gangisetty, 2018; Selko, 2011) (Fig. 3). These structures
are also present in other neurodegenerative diseases, such as Parkinson’s disease, where they
are known as tauopathies.

Figure 3. Human tissue from the hippocampal region of the brain. Intracellular tau protein
tangles are stained brown, forming triangular shapes in excitatory neurons. Amyloid-β
proteins comprise the sparse, round structures within the extracellular matrix. Credit:
Washington University School of Medicine (Kauwe et al., 2008)
Aside from protein aggregates, neuroscientists have also characterized AD as a
disorder of neuronal loss. With disease progression comes a loss of connectivity between
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neurons and their subsequent atrophy of brain tissue and cell death. These biological markers
are well-recognized and reliably-characterized in post-mortem brain samples. However, little
is still known about the disease’s underlying risk factors and the molecular mechanisms
implicated in disease progression (Freytag et al., 2018). The previously mentioned
biomarkers, or, more accurately, necro-biomarkers, reflect a considerable challenge in AD
research; a definitive diagnosis of AD can only be made during a neuropathological
examination during autopsy, due to the relative inaccessibility of cortical tissue and the lack
of reliable biomarker for complex pathologies. Therefore, there is a vested interest in the
diagnostic and prognostic applications of a reliable clinical endophenotype for this disorder.
There are two types of AD recognized by the National Institute on Aging: familial
and sporadic, characterized by early- and late- onset, respectively. Familial Alzheimer’s
Disease, of the early-onset variety, only accounts for 5% of AD cases. It is caused by discrete
genetic mutations, passed through families. In these families, symptoms typically present
well before the age of 65, sometimes as early as 30 or 40 (Donovan et al., 2014). Three genes
have been associated with Early-Onset Familial Alzheimer’s Disease (EOFAD), and
mutations in these genes follow a pattern of autosomal dominant inheritance. They are the
amyloid precursor protein (APP) on chromosome 21, presenilin 1 (PSEN1) on chromosome
14, and presenilin 2 (PSEN2) on chromosome 1. Each presenilin gene encodes an enzymatic
unit involved in the metabolism of APP; mutations of these genes can result in the specific
cleavage of APP which results in Aβ, the toxic specie. These extracellular proteins aggregate
to form dense plaques. The predictability of EOFAD and its pathogenic loci has created a
platform for the critical research into other variations of AD, including the more-common
late-onset form. By observing AD-related neurological changes that occur in these families
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before cognition deficits appear, researcher hope to link the formation of brain abnormalities
with disease development and its underlying mechanisms that can be applied to the more
common form of AD.
The more common form of AD, Late Onset Alzheimer’s disease, is characterized by
symptom manifestation in the mid-60s and later. While its cause and mechanisms are not yet
completely understood, they are likely to include a combination of a complex genetic
architecture and environmental and lifestyle risk factors. In the last five years, however, one
reliable candidate gene has been found to moderate AD risk. The apolipoprotein (APOE)
gene, located on chromosome 19, presents in three alleles: ε2, ε3, and ε4. APOE ε2 is a
relatively rare allele which protects against disease risk. It is thought that this allele delays
the onset of AD in these individuals, compared to APOE ε3 or APOE ε4 variants (Liu et al.,
2013). APOE ε3 is the most common allele for this gene. It is believed to play a neutral role
in the disease, neither increasing nor decreasing risk of acquisition. The APOE ε4 allele,
however, substantially increases risk for AD and has been linked to an earlier age of onset.
The number of APOE variant alleles in an individual’s genotype significantly alters their
susceptibility to AD (see Appendix A). About 25% of the population is heterozygous for
APOE ε4, corresponding to a three-fold increased risk for AD. An individual who is
homozygous for APOE ε4, which occurs in approximately 1% of the population, has a ten- to
12-fold increased risk of developing AD (Verghese et al., 2011). While a blood test can
identify which APOE alleles a person has, these results are unreliable for predicting who will
or will not develop the disease and to what severity.
As a heterogeneous disease attributed to a vast number of combining genetic and
environmental factors, the most important and most reliable risk factor for AD is age (Ridge
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et al., 2013; Weill Institute for Neurosciences, 2018). Specifically, it appears that AD is not
simply an accelerated progression of the normal aging process, but, rather, a systemic pattern
of dysregulated aging; genetic research speculates that this dysregulation may induce
disordered changes to the structure of chromatin, the condensed configuration of DNA. In
this disease, genetic factors do not act alone and are joined by a host of potentially harmful
environmental and lifestyle influences. Environmental and behavioral risk factors include
hypertension, estrogen supplements, smoking, stroke, heart disease, depression, arthritis, and
diabetes (Cornuitiu, 2015). Additionally, some lifestyle choices appear to decrease the risk of
AD, including exercise, intellectual stimulation, and maintaining a Mediterranean or
pescatarian diet (Ridge et al., 2013). Contemporary research seeks to link these external
factors to biological mechanisms for a more comprehensive understanding of disease risk
acquisition and protective elements.
Research from Lunnon et al. (2014) outlines two specific reasons as to why causeand-effect research is particularly challenging for AD. First, brain tissues are uniquely
inaccessible, and, second, this age-related disorder is poorly suited for longitudinal study. By
the time AD-related cognitive deficits manifest, there are a number of age-confounding
variables which only increase, further complicating symptomatologic observations.
Furthermore, the etiological process of AD remains unknown, resulting in an unclear
timeline of symptom manifestation and underlying biological dysfunction. In order to best
model AD and other complex disorders, two main models have been proposed for its study.
“Two seemingly contradictory hypotheses exist about the architecture of complex disease:
the common disease/common variant hypothesis and the multiple rare variant hypothesis. In
the first, many common variants of small effect size collectively explain disease risk, while
in the second, rare variants, some with large effect and high penetrance, explain disease risk.”
(Ridge et al., 2013; Singleton & Hardy, 2011).
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Singleton & Hardy (2011) suggest that these hypotheses may not be mutually
exclusive; the genetic landscape governing complex diseases, such as AD, is likely a hybrid
of the two possibilities. They suggest that both common and rare variants are efficacious in
increasing or decreasing disease risk, and, very often, they are found in the same loci, called,
“pleomorphic risk loci” (Ridge et al., 2013; Singleton & Hardy, 2011). The ability for
research teams of today to model genetic variants across a prevalence and effect size matrix
provides a blueprint for the design and development of efficacious therapeutic interventions.
As a complex disorder with genetic influences and a great investment into its treatment, AD
poses an attractive disease by which to apply a pleomorphic risk strategy.
The co-occurrence of AD large body of research, epidemic possibility, steadfast
financial and scientific investment in the search for answers in heritability and causation, and
the current limitations of traditional brain imaging research methods make the disorder the
prime candidate for utilizing the newer, promising modes of genetic research. The advent of
more complex, high throughput next generation sequencing and the falling costs of this
technology make this an ideal time to expand AD research into previously unexplored
territory, such as seeking out rare variants or continuing the search for a reliable genetic
biomarker. As a model system, it is hoped that the devotion to comprehending AD will yield
clues to understanding other neurodegenerative disorders for which there is not yet such a
large literature base.
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Section III. Uncovering the Missing Heritability of Alzheimer’s Disease
Heritability is defined as the proportion of variance in a disease that can be explained
by genetic variation. More precisely, heritability is the proportion of variance due to the
effects of additive genetic components, including allelic variants, epistatic interactions, or
DNA sequence variants. As it pertains to human disorders, a seminal work on inheritance
explains that “the variability of presentation of...complex diseases has a component of
quantitative inheritance, consisting of the effects of different allelic forms that interact with
each other and with the environment” (Blanco-Gomez et al., 2016). In an effort to uncover
the genetic architecture underlying such common, complex disorders, as well as rare
Mendelian diseases, research teams of the early 2000s relied on the momentum and data
stemming from the Human Genome Project. Their goal was to determine genetic risk factors
for diseases and use them to make predictions about the dysfunction and biological
mechanisms underlying an individual’s risk.
The culmination of these efforts was the birth of the genome-wide association study
(GWAS), which produces replicable DNA sequence variations for a given phenotype. Using
microarrays containing millions of single nucleotide polymorphisms (SNPs), collaborative
GWASs have identified variants linked to complex diseases and traits (Lord & Cruchaga,
2014; Tak & Farnham, 2015) (see Appendix A). In a clinical case, GWASs rely on
differences in the frequency of a specific SNP in healthy (or control) vs. diseased (or case)
populations. When a SNP is identified by GWAS to be statistically significantly
overrepresented in a disease population, it is called a risk-associated SNP; the surrounding
genetic regions containing such SNPs are called risk loci for that particular disease. These
studies into genetic variation help in identifying possible regions of the genome that are
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implicated in the onset and progression of a disease. Advancements in the accuracy, speed,
and cost of genotyping and its complementary analytical software have resulted in the
identification of well-validated genetic candidates of risk for common disorders, such as
arterial disease or type 2 diabetes (Freytag et al., 2018). Recognizing these genetic risk loci
and understanding their underlying molecular mechanisms and functional relevance are two
different things, however.
It is difficult to understand disease risk from GWAS results for a number of reasons,
including individual SNP power and its location within the genome. Not all SNPs incur the
same amount of risk for a disease, and, similarly, the presentation of SNPs in a genome does
not suggest additive risk accumulation. Most GWAS-identified SNPs, either directly
genotyped or imputed, are located in non-coding regions of the genome, presenting a puzzle
as to how a single-nucleotide change in such regions can confer conditional risk of a disease
(Tak & Farnham, 2015). In fact, some estimates indicate that most disease-associated index
SNPs, about 88%, are located in non-coding regions of the genome, almost equally divided
between intergenic (43%) and intronic (45%) regions (Blanco-Gomez, 2016; Tak &
Farnham, 2015). To reconcile the influence of intronic variation, a current hypothesis
presents the possibility that individual SNPs induce changes in gene expression levels as a
post-translational modification, rather than the direct protein creation and function that might
be seen from exonic variation. Because of this, it is critical moving forward to identify both
the direct target of a risk-associated element and other genes affected by a change in
expression levels of these direct targets, thereby integrating traditional genomic approaches
with evolving expression-based approaches.
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Figure 4. A
chromosomal
ideogram displaying
the 50 most significant
loci for AD uncovered
by GWAS, using the
genetic risk score
algorithm designed by
Chauhan et al. (2015).
Teal dots represent
individual loci.
Specific gene names,
locations, and
functional relevance
can be found in
Appendix B.

Since their inception in 2002, GWAS have been very successful in identifying
broader genetic regions associated with complex traits. Using these results, neuroscientists
and geneticists have identified a number of candidate regions of interest along the genome
that may contribute to an increased risk for late-onset AD (Donovan et al., 2014; Harari &
Cruchaga, 2016) (Fig. 4). These regions, scattered across the genome, include genes which
encode conformational changes in proteins and moderate inflammatory response, enzyme
activity, and more. Each genetic loci represents a region which, when altered in an
individual, manipulates their susceptibility for AD, based solely on genetic sequence. By
design, GWAS studies are aimed at identifying common variants, and, as such, they are
inconclusive in explaining the full heritability to intricate, multifactorial phenotypes, such as
AD. Although many large GWAS publications on AD have been performed and replicated, a
major part of the genetic component to phenotypic variability and susceptibility still has not
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been found, a predicament known as “missing heritability,” (Blanco-Gomez et al., 2016). In a
meta-analysis of twin studies, it had been proposed that up to 80% of risk for Late-Onset AD
is predicted to be accounted for by genetic influences, though the aforementioned variants
account for less than 40% of the genetic component for AD (Allen et al., 2014).
Two research teams in the last five years have sought to uncover the magnitude of
this missing heritability. A meta-analysis conducted by Lee et al. (2011), observing 3,333
cases and 3,924 controls, including 2,699 population-based estimated that common genetic
variants, such as those discoverable in a GWAS, account for 24% of variance in AD. The
same analysis gauged the contribution of the APOE gene, using several proxy SNPs with
varying degrees of linkage disequilibrium; their estimate of the APOE effect was
approximately 4%, though their review considered only directly genotyped SNPs (Lee et al.,
2011). An analysis published by Ridge et al. (2013) reviewed both genotyped and HapMap
imputed SNPs (see Appendix A). Using the Alzheimer’s Disease Genetics Consortium
(ADGC) dataset described by Naj et al. (2011), Ridge et al. (2013) note that, across all
2,042,116 SNPs imputed in the HapMap, 33.1% of phenotypic variance is explained. From
the same data set, they note that the APOE ε2 and ε4 alleles, which are those that contribute
to AD risk, account for 5.9% of the phenotypic variance. These estimates are significantly
less conservative than those determined by Lee et al.. Leveraging these analyses, it is
estimated that the missing heritability for AD in the post-GWAS era is about 65%.
In a genome-wide distribution analysis, Ridge et al. (2013) surmised that
chromosome 19 accounted for the highest proportion of phenotypic variance. After
accounting for the 11 most significant pre-established AD loci, this variance, when assigned
across somatic chromosomes, denotes chromosomes 1, 4, 5, and 17 as those accounting for
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the largest percentages of unexplained phenotypic variance (Fig. 5B). They found that each
of those chromosomes accounts for more than 2% of variance while chromosomes 9, 14, and
21 account for the least variance, at roughly 0.0001% each (Ridge et al., 2013). Considering
what has already been established regarding the influence of the APP gene on chromosome
21 and PSEN1 on chromosome 14 in EOFAD development and their functional relevance to
the production of amyloid-β aggregations, this research suggests that there are other
significant regions of the genome that demand attention in uncovering moderators of AD
risk.

A.

B.

Figure 5. A. Unexplained AD
variance, by chromosome. In this
figure, Ridge et al. (2013) show
phenotypic variance explained by
all SNPs. Error bars correspond to
standard error (Ridge et al., 2013,
Fig. 1). B. Unexplained AD
variance, by chromosome,
excluding known AD markers.
After accounting for the most
significant AD-associated SNPs,
explained phenotypic variance
shifts to highlight other
chromosomes (Ridget et al., 2013,
Fig. 2).
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Though the establishment of relevant AD loci has become tremendously thorough
and targeted, GWAS research is reaching a limit to the amount of heritability it can explain.
The circumscription of GWAS has ushered in a new generation of research, one which seeks
to explore the epigenome and enrich our understanding of complex disease etiology and
pathogenesis through non-sequence alterations (Klein et al., 2016). A common complication
to genetic research is interpreting the biological distance between a genetic polymorphism
and its consequences in a tissue of interest. Publications by Freytag et al. (2018) propose that
this gap may be reduced through the interrogation of molecular mediators, such as gene
expression. AD investigations have been at the forefront of this discipline, due to its global
health interest, substantial funding, and previous body of research; in fact, it was a study into
AD which produced the first independently replicated associations of an epigenomic marker
for a disease (Klein et al., 2016).
This inflection point to the field is hinged on the implication of new areas of the
genome involved in disease, including locating epigenetic targets for these traits. In the
neuropsychiatric sphere, DNA methylation and chromatin structure of human brain tissue are
proving pivotal points for facilitating ongoing genetic research (Klein et al., 2016). In their
epigenetic review of AD, Freytag et al. (2018) write that “the integration of transcriptomics
data in the study of the genetic factors of complex traits has significantly improved our
understanding of their genetic basis. Thus, methods that reduce the gap between genetic
susceptibility [estimates] and their functional [consequences] are expected to increase our
understanding of the genetic underpinnings of genetically complex traits.” With advancing
technology and dropping costs to epigenetic research, the field of clinical genetics is
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expected to shift to include complementary EWAS investigations in tandem with GWAS
results.
The epigenome offers an attractive solution to capture information not just about
actively transcribed genes, but also those genes which have the potential to be expressed in
the presence of a particular stimulus. The effect of the environment into cognitive principles,
such as brain development, learning and memory, and other higher-level cognitive functions
is one of the earliest and foremost implications of epigenetic mechanisms in neuroscience
(Gangisetty, 2018). The following generation of epigenomic studies in Alzheimer’s Disease
seeks to isolate the effects of AD compared to standard effects of aging. Previous research
had been difficult to interpret for a variety of reasons, including small sample sizes; the lack
of accounting for confounding variables, such as age; and a lack of replication in independent
samples (Klein et al., 2016). The sequential replication design across multiple tissues utilized
by Lunnon et al. (2014) represents the first epigenome-wide association study (EWAS) of
AD. This style of association study is motivated by an increasing knowledge of the
architecture of the genome. In turn, the results of these studies better informs the epigenetic
landscape of complex disorders and affirms the promising relevance of epigenetic variation
in human health and disease.
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Section IV. Alzheimer’s Disease’s Epigenetic Landscape
Understanding the epigenetic events underlying complex phenotypes is one of the
first steps in increasing our knowledge of the biology of disease and constructing successful
therapeutic efforts for historically untreatable conditions, like psychiatric and
neurodegenerative disorders. Epigenetic changes are known to be implicated in a number of
complex traits and syndromes, including some kinds of cancer and diabetes, Prader-Willi
syndrome, and Angelman syndrome (Harari & Cruchaga, 2016). These mechanisms can alter
gene expression with respect to the brain in memory formation and learning, two character
hallmarks of dysfunction to AD. While genetic variation via SNPs or other sequence based
variants are considered to be unchangeable, the epigenome is highly plastic. Epigenetic
modifications exercise control through transcriptional activity and gene expression, making
them reversible and susceptible to manipulation. Such markers respond uniquely to an
individual’s environment and life experiences and can precede disease pathology, indicating
their potential as diagnostic tools or indicators of risk (Kelly et al., 2010). Each cell has its
own distinct epigenome, featuring up to 40 different currently-defined epigenomic features,
including DNA methylation, histone acetylation, chromatin alterations, X-inactivation, and
imprinting. While this cellular heterogeneity makes tissue-level profiling a challenge in
interpretation, it also contributes helpful information to the greater understanding of disease
complexity. Furthermore, because epigenetic marks are hereditable and reversible, they have
emerged as targets for clinical interventions and carrier research.
“Epigenetics” first made its way into empirical vocabulary in 1939, with geneticist
Conrad H. Waddington’s attempts to reconcile the old biological debate between epigenesis
and preformationism. The term was proposed to describe the carefully-orchestrated
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molecular events which take place in early embryonic development, using the Greek root for
“over” or “above” to illustrate interacting mechanisms which give rise to variation in tissue
and organ type not already present in a single gamete (Waddington, 1939). Today,
epigenetics refers to a dynamic field which encompasses heritable changes in gene
expression that do not involve changes to the underlying DNA sequence. As such, these
changes can vary across time and tissue, unlike DNA, whose pattern is precisely replicated
for all cells in a given individual, assuming no mutation. While some of these changes are
inherited from parents, many, if not most, are acquired through environmental or lifestyle
effects and can remain stable for long periods of time (Klein et al., 2016). The most common
epigenetic events in relation to disease are DNA or chromatin alteration, as well as RNAmediated modifications.
DNA Methylation
In part due to its relative ease of access in human brain tissue, most aging studies
have focused on the epigenetic target of DNA methylation. Longitudinal surveys of samples
from the human prefrontal cortex (PFC) have uncovered large differences in methylation
over early development and aging. The latest advances in technology enable researchers to
screen for methylated regions of the genome, using large numbers of samples in commercial
genomic arrays. Methylation is, by definition, the addition of a methyl molecule in a CpG
group of DNA; the downstream effects of methylation present a powerful mechanism for
silencing gene expression (Harari & Cruchaga, 2016). The addition of methyl groups to DNA
is a normal event that acts to stabilize the genome, as large quantities of DNA could
otherwise interact in unpredictable recombination events or induce transcriptional
dysfunction of nearby genes. The knowledge of these general patterns of methylation
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establish a foundation upon which further studies may be conducted into the extent,
mechanisms, and causes of interindividual DNA methylation variance and disease.
Furthermore, there are a number of factors known to contribute to changes in methylation
levels across the genome, including carcinogen exposure, such as tobacco, alcohol, arsenic,
and asbestos; subjection to heavy metals; and diet. These environmental factors alongside the
standard aging process have been hypothesized to influence clinically significant changes in
the methylome.
The normal aging process induces a shift in the distribution of methylation across the
genome. In older organisms, DNA hypomethylation results in a widespread reduction of
inhibition across the genome, but, in some regions, DNA hypermethylation can also occur. In
such cases of hypermethylation, which largely occur in promoter regions, many older
patients show reduced gene expression (Gangisetty, 2018). Because the observed pattern of
age-associated methylation is consistent in various tissue types, Christensen et al. (2009)
suggest a common mechanism of dysregulation underlying the alterations. They propose a
reduction in maintenance and precision of methyltransferases with aging in the case of
hypomethylation or a potential accumulation of stochastic methylation events over time, in
the case of hypermethylation. While the samples studied here do not present disease
etiologies, the accumulation of epigenetic changes without detectable phenotypes cannot be
written off as insignificant; furthermore such information can provide a baseline by which to
distinguish and compare methylation levels between AD and older populations. It is
possible, if not probable, that age-related drift without dramatic changes in gene expression
may confer an increased susceptibility to disorders. The potential to increase pathological

ENDOPHENOTYPE FOR ALZHEIMER’S DISEASE

29

risk can depend on the likelihood and frequency of methylation alterations, modifying overall
genome stability.
Through three independent post-mortem cohorts, Lunnon et al. (2014) conducted a
cross-tissue analysis of DNA methylation in AD. They identified a region within the ankyrin
1 (ANK1) gene that is differentially methylated from healthy controls. The ANK1 gene
encodes a brain-expressed protein involved in the organization of neuronal plasma
membranes (Lunnon et al., 2014); previous research associates the gene with neuropathology
in the entorhinal cortex (EC). This gene was confirmed to be significantly hypermethylated
in two other cortical regions: the superior temporal gyrus and the prefrontal cortex (Lunnon
et al., 2014). The cerebellum, which is largely protected from the neurodegenerative
processes in AD, did not show this pattern of hypermethylation. De Jager et al. (2014)
confirmed 71 discrete CpGs corresponding to 60 differentially methylated regions, including
two previously identified AD-associated loci identified by GWAS. Their results
demonstrated that many of these differentially methylated positions were linked to genes
within known AD susceptibility networks. These networks were derived from protein-protein
interactions, rare variant studies, and GWAS candidate genes. This study presents one of the
earliest robust association studies between AD and methylation patterns in brain regions
known to be affected by the disease. It also establishes that simply averaging methylation
measures over a gene is overly simplistic; the context of each CG-methylation is crucial to
interpreting the effect size of an epigenetic change.
Histone Modification and Chromatin
Apart from DNA methylation, another group of prevalent, influential epigenetic
marks is the class of histone modifications. This category refers to post-translational changes
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that affect the wrapping and condensation of genetic material. DNA is wrapped around
histone proteins to form nucleosome “beads on a string” (see Appendix A). This binding is
one of the initial steps in condensing genetic material into the densely-packed chromatin. The
normal biological aging process is characterized in part by a loss of heterochromatin, the
compressed form DNA known to play a role in gene expression. This loss is demonstrated by
DNA hypomethylation, the absence of heterochromatin marker H3K9me3, and selective
dysfunction of the nuclear lamina (Klein et al., 2016). Histone modifications, such as
acetylation, cause DNA to wrap more loosely around a histone protein, allowing for more
gene activation via exposure. Acetylation is a dynamic and reversible process, regulated by
histone deacetylases (HDACs) and histone acetyltransferases (HATs).
In the diseased aging process, covalent modifications begin to alter chromatin
structure. For diseases associated with aging, such as AD, it would seem that histone
modifications due to disease progression are joined by those induced in normal aging,
producing a combined model of chromatin instability and additional malfunction in regulator
binding, transcriptional initiation, and activity at enhancer regions (Gangisetty, 2018). In
replicable animal models, global histone acetylation occurs in repetitive DNA elements in
older mouse brains, which suggests a loss of chromatin integrity with age. Recent research
has linked HDAC2 to the brain as an important regulator for synaptic plasticity and memory
encoding, storage, and retrieval; an abundance of HDAC2 complexes resulted in increased
synapse numbers and memory facilitation. Notably, this deacetylase has been shown to be
disrupted in AD-associated processes, supporting the role of histone acetylation and
deacetylation in AD (Guan et al., 2009; Li et al., 2008). The potency of histone
modifications and loss of chromatin integrity with age or disease progression reinforce a
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recurring theme using epigenetics to unearth larger biological and clinical implications in the
future.
Research into the most common forms of histone modifications and their impact on
AD pathology found that histone acetylation has an active role in disease susceptibility.
Recent observations have tagged chromatin marker H4K16 for its implications in aging and
neurodegeneration (Nativio et al., 2018). An analysis on the acetylation of H4K16
(H4K16ac) revealed a significant redistribution of marker between AD brains and matched
age controls. Throughout the normal aging process, the amount of H4K16ac found across the
epigenome increases to promote control over higher-order chromatin and regulate
interactions at the level of the nucleosome. However, in AD brains, there is a marked loss of
this epigenetic feature, particularly occurring near genes related to the AD and aging (Nativio
et al., 2018). These findings suggest a model in which AD is more than an advanced state of
the normal aging process; rather, the dysregulation of aging seen in AD pathology may
induce structural and functional changes to genetic material, such as chromatin integrity. It
also implies a mechanism by which health brains bear protective epigenetic marks that, when
dysregulated, increase an individual’s risk for disease development.
Non-coding RNAs
Since the transcription of non-coding RNAs (ncRNAs) is under direct epigenetic
regulation, ncRNAs are implicated in a number of epigenetic processes, such as DNA
methylation and histone modifications. ncRNAs are able to target enzymatic components of
epigenetic machinery; as a result, they can directly influence the levels of RNA expression
through other mechanisms, such as microRNA-related RNA degradation (Klein et al., 2016).
Historically, most studies that have focused on small, non-coding RNAs revolved around
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microRNAs, but the importance of long non-coding RNAs has become more evident in
recent years. microRNAs (miRNAs) are small, no more than 20-24 nucleotide bases in
length. They regulate gene expression post-transcriptionally by blocking translation or
inducing the degradation of mRNA (Li et al., 2008). While many miRNAs are expressed
throughout the human body, the brain shows an especially high presence of miRNAs. This
suggests that miRNAs might play a role in neuronal development, function, and aging
(Gangisetty, 2018). The role of miRNAs in AD has been observed in adult forebrains in
knockout genetic studies. Using peripheral blood mononuclear cells, researchers found that,
in an epigenomic profile of aging, the majority of miRNAs decrease with age. In particular,
they found and validated nine different miRNAs that were significantly lower in older
individuals compared to younger subjects, suggesting several regions of regulatory
dysfunction with age (Noren Hooten et al., 2010).
Long non-coding RNAs (lncRNAs) are defined as heterogeneous regulatory elements
greater than 200 nucleotides in length. At a lower level of function, lncRNAs are involved in
post-transcriptional modifications, such as mRNA stability, splicing, and translation. Their
higher-level applications are vast, spanning a number of biological processes, such as
development, cell differentiation, cell survival, apoptosis, gene imprinting, and stem cell
maintenance (Gangisetty, 2018). When lncRNAs couple with chromatin-remodeling or
histone-modifying complexes, such as polycomb repressive complexes (PRCs) and HDACs,
they can serve as scaffolds for molecular transport. For example, one such scaffold can
mediate the recruitment of PRCs to necessary genomic regions to guide the regulation of
transcription (Gangisetty, 2018). During aging, the abnormal expression of ncRNAs results
in widespread defects in several chromatin-related processes; these defects imply that
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ncRNAs are functionally associated with the stability and integrity of chromatin and, thus,
can be implicated in aging mechanisms. Various examples of lncRNA dysregulation have
been implicated in AD. For example, BACE1-AS is an abundantly expressed lncRNA within
several brain regions of AD patients, which regulates the expression of BACE1, which is
critical in AD pathophysiology (Gangisetty, 2018). Other lncRNAs are implicated in the
prefrontal association areas and hippocampal regions of AD brains, suggesting a role for
these epigenetic modulators in the regulation of synaptic plasticity and strengthening of
neural networks.

Recent evidence suggests that epigenetic mechanisms play a pivotal role in
neurodegenerative processes, including DNA methylation, histone modifications, and noncoding RNAs. This research has contributed to growing evidence for epigenetic modulation
and mediation of risk for AD. An epigenomic review of AD reveals a significant, selective
reduction in the expression of genes associated with synaptic plasticity. The loci for
epigenetic marks, including chromatin alterations, associated with these expression changes
correlate with impaired plasticity and cognitive networks. Furthermore, inflammatory and
immune response genes demonstrated increased activation (Gangisetty, 2018). The natural
products of epigenetic modifications present a promising treatment strategy for complex,
multifactorial neurological disease. Clinical epigenetics seeks to provide insights into the
molecular basis of polygenic disorders by narrowing “the biological gap between genetic
variation and its functional impact,” through such epigenetic moderators (Freytag et al.,
2018).
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Table 1. Regional distribution of loci which are epigenetically modified in AD pathology
(Absalon et al., 2013; Gangisetty, 2018; Li et al., 2008; Lord & Cruchaga, 2014).
Gene
MIR34A
MIR137
MIR181B
MIR291
S100A2
TMEM59
MIR128
MIR16
NEP
MEF2C
MIR146
MIR106B
ANK1
CLU
ANRIL
MIR24
CDH23
miR-103
Sirt1
miR-107
BACE1
Kcnq1ot1
miR-130a
RB1
miR-496
ADAM10
miR-1538
RPL13
miR-101
RHBDF2
APOE
MIR125
miR-644
miR-645
miR-155
APP
miR-221

Locus
Chromosome 1 (9151668-9151777)
Chromosome 1 (98046070-98046171)
Chromosome 1 (198859044-198859153)
Chromosome 1 (155335261-155563160)
Chromosome 1 (153561108 -153565830)
Chromosome 1 (54026681-54053573)
Chromosome 2 (135665397-135665478)
Chromosome 3 (160404745..160404825)
Chromosome 3 (155024124..155183729)
Chromosome 5 (88699654 - 88922692)
Chromosome 5 (160485352-160485450)
Chromosome 7 (100093993-100094074)
Chromosome 8 (41653225-41896762)
Chromosome 8 (27596917-27615031)
Chromosome 9 (21994791-22121097)
Chromosome 9 (95086021-95086088)
Chromosome 10 (71396934-71815947)
Chromosome 10 (89592747-89592827)
Chromosome 10 (67884669-67918390)
Chromosome 10 (89592747-89592827)
Chromosome 11 (117285686-117316256)
Chromosome 11 (2608328-2699998)
Chromosome 11 (57641198-57641286)
Chromosome 13 (48303747-48481890)
Chromosome 14 (101060573-101060674)
Chromosome 15 (58595204-58749978)
Chromosome 16 (69565808-69565868)
Chromosome 16 (89560657-89566829)
Chromosome 17 (72121020-72126420)
Chromosome 17 (76470893-76501440)
Chromosome 19 (44905749-44909395)
Chromosome 19 (51693254-51693339)
Chromosome 20 (34466325-34466418)
Chromosome 20 (50585786-50585879)
Chromosome 21 (25573980-25574044)
Chromosome 21 (25880550-26171128)
Chromosome X (45746157-45746266)
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Figure 6. A chromosomal
ideogram displaying the
most significant
epigenetically moderated
loci for AD, represented
by green dots. Significant
loci were determined
using the genetic risk
score algorithm designed
by Chauhan et al. (2015).
(Absalon et al., 2013;
Gangisetty, 2018; Li et al.,
2008; Lord & Cruchaga,
2014) .

The epigenetic interface between environmental and genetic risk factors has
developed significantly in the last several years, with growing promise of disentangling
complex etiologies. Likewise, the advancement of clinical epigenetic research offers a
promising supplement to traditionally-restrictive GWAS studies. The field of epigenetic
epidemiology is a new endeavor, with large potential and matched limitations. The intricate
composition of neurodegenerative disorders necessitates these alternative research methods,
and, although epigenetics has greatly aided the pursuit of diagnostic and therapeutic targets,
it fails to holistically encapsulate the diseases on its own. The relative adolescence of
epigenomic studies alongside the continual difficulty in recognizing and diagnosing AD
makes this research vulnerable but nonetheless important. In this field, confounding age
variables and the pathophysiology of preclinical AD are added to an already complex matrix
of challenges to this research, joined by measurement variability and small subject
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populations. Designing a powerful epigenomic study in humans requires the careful
consideration of tissue- and cell-type targets and their respective epigenetic marks.
Despite their limitations, the body of literature and emerging epigenetic studies
document a number of genomic regions where changes in epigenetic marks are reproducibly
happening in the cortex of older individuals who have accumulated AD-related pathology.
Figure 6 displays a genome-wide array of loci that are epigenetically altered in AD samples,
compared to controls. Table 1 describes these loci geographically by name. Recognizing
these regions as potential loci for disease risk manipulation not only improve diagnostic
efforts for complex disorders, like AD, but it also introduces the possibility for longitudinal
study that has been a challenge for neurodegenerative disorder. As an age-related disease in
very inaccessible tissue, AD research and clinical implications would benefit greatly from
being able to detect epigenetic changes in an individual over time. Furthermore, such cues
would better inform what is currently known about environmental and lifestyle factors which
modulate disease acquisition. Even with a finite number of epigenetic loci, however, such
research is not entirely cost- or labor-effective at present. As these technologies develop,
accessibility, too, advances; however, at present, the field would benefit from pinpointing a
few selected loci for further research and detection, rather than casting such a wide net.
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Section V. Neurogenesis and AD Pathology
“Once development was ended, the fonts of growth and regeneration of axons and dendrites
dried up irrevocably. In adult centres, the nerve paths are something fixed and immutable:
everything may die, nothing may be regenerated. It is for the science of the future to change,
if possible, this harsh decree.” (Cajal, 1913).
Spanning into the late 20th century, neuroscience held, as one of its central tenets, the
“no new neurons” doctrine. It was assumed that all neurons are generated exclusively during
prenatal development and very early into postnatal life. In the adult brain, neurogenesis was
considered to be nonexistent. The doctrine was initially outlined by Santiago Ramon y Cajal,
but its reconsideration did not come until the 1960s and 1970s, when it was experimentally
challenged and thrown out, with Dr. Joseph Altman’s seminal discovery of thymidine-H3labelled neurons and neuroblasts in adult rat brains (Altman & Das, 1965; Rodriguez &
Verkhratsky, 2011). The discovery of the human brain’s ability to produce new neurons
came no more than several decades ago, with the observation that the olfactory bulb is able to
incorporate newborn neurons throughout adult life. Since then, researchers have learned that
particular regions can produce completely immature neurons which are subject to a unique
selection process and migration (Lledo et al., 2006). This process, known as neurogenesis, is
a useful way to build and repair circuits and construct networks of sharing information,
including the passage of short-term memories to long-term storage.
Today, neuroscientists regard neurogenesis to operate primarily in two main areas of
the adult mammalian central nervous system: in the anterior region of the subventricular zone
(SVZ) along the lateral ventricles and in the subgranular zone (SGZ) of the dentate gyrus
(DG) of the hippocampus (Rodriguez & Verkhratsky, 2011). These areas are known as
neurogenic niches, containing multipotent neural stem cells (NSCs). The NSCs that
demonstrate a slow self-renewal go on to produce neural progenitor cells (NPCs) with a
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faster-dividing cell cycle. These neural precursors ultimately differentiate into neuroglia or
neurons, which can migrate into the cell layers these regions and integrate into local circuitry
(Seri et al., 2001). Based on observations in rat models, it is estimated that the healthy
processes of adult mammalian neurogenesis contribute thousands of new neurons each day to
the hippocampal regions. Growing research promotes the role of new neurons in
strengthening pre-existing cognitive networks and promoting olfaction- and hippocampaldependent learning and memory behaviors. Trouche et al. (2009) demonstrated that newlyintegrated neurons within the granule layer of the dentate gyrus are recruited in contextdependent ways, contributing to strengthening memory circuits related to a given stimulus. In
studies involving mouse models, environmental enrichment has shown to be very influential
in correlating neurogenesis and spatial memory tasks (Gage, 2000). These findings suggest
that deficits in neurogenesis may negatively impact the plasticity of the hippocampus and its
associated neural circuitry.
Neurogenesis has become a topic of intense study in recent years as neuroscientists
interrogate the birth of new neurons in their role within neurodegenerative disease etiology
and progression. An exploration of AD pathology would be remiss to exclude a
comprehensive look at the hippocampus. Linked frequently to memory encoding, the
hippocampus is also associated with affective behaviors and emotions (Jahn, 2013). Lesionbased and knock-out studies into the olfactory bulb and hippocampus show that damage to
these areas correlates with common early symptoms for AD, including olfactory deficits and
difficulty in declarative memory tasks (Jahn, 2013). It is altogether very possible that the
observed neurogenesis alterations contribute to the disease’s progressive loss of memory and
that ongoing cognitive dysfunction be enhanced by a compromised neurogenic system.
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Furthermore, neuropathological staging of protein deposits, including intracellular tau tangles
and insoluble extracellular plaques of amyloid-β peptides, show that early sites of aggregate
formation include the olfactory bulb and hippocampal formation (De la Rosa-Prieta et al.,
2016). These neuroimaging results further highlight these regions as pivotal in
neurodegeneration and implicate neurogenesis as a mechanism by which AD pathology
develops and progresses.
There exists an unmistakable overlap between the neurogenic dysfunction and the
corresponding functional manifestation in disorders like AD. However, AD and adult
neurogenesis are not only linked by shared locality of sites where early pathological
impairments occur; rather, the two share a number of common molecules, as well, which are
utilized in both processes. Newer evidence suggests that several of the molecular players in
AD play a role in adult neurogenesis, including the amyloid precursor protein (APP) and
presenilin 1 (PSEN1) and their metabolites (De la Rosa-Prieta et al., 2016). In the adult SGZ,
expression of PSEN1 and other presenilin variants linked to AD correspond to impairments
in microglia proliferation and cell differentiation (Choi et al., 2008). The inactivation of
PSEN1 in the forebrains of AD mouse models affected environmental enrichment-induced
hippocampal neurogenesis (Feng et al., 2001; Ming & Song, 2011). These animal models and
other PSEN1 mutants have exhibited deficiencies in neuronal regeneration, cell
differentiation among neural precursors, and impairments of dendritic growth of newborn
neurons in the adult SGZ (Li et al., 2008; Ming & Song, 2011). Tau hyperphosphorylation in
SVZ striatal neurons and in DG neurons can impair the maturation and network connectivity
of newly-formed cells (Hamilton et al., 2010; Rodriguez & Verkhratsky, 2011). These
findings suggest that not only are neurodegenerative diseases, namely AD, disorders of tissue
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death and synapse decay, but the pathology also incorporates dysfunction in new cell
development, differentiation, and migration in cognitive networks.
Because AD, like all other forms of dementia, is a process exclusive to humans,
substantial efforts have been directed into designing relevant animal models to reflect the
neuropathological, biological, and behavioral alterations seen in humans. The unique
properties of neurogenesis and neurodegeneration in humans means there is no perfect
animal model for Late-Onset AD. Most of the transgenic experimental mice most closely
resemble rare familial variants of AD (Jaworski et al., 2010). Many studies performed on
transgenic animals expressing the mutant form of the amyloid precursor protein (APP) result
in dysregulated neural progenitor cell proliferation (De la Rosa-Prieta et al., 2016; Rodriguez
& Verkhratsky, 2011). These complex changes to neurogenesis associated with AD require
many follow-up experiments to clarify, especially since these models represent a limited
profile of AD’s structure. However, just as clinical researchers put emphasis on the rare
forms of AD, studying rare variants in animal models is similarly effective in understanding
the underlying mechanisms to AD. Other difficulties associated with modeling
neurodegeneration in animals include distinguishing disordered processes from normal aging
systems and quantifying neurogenic rates in mice across variable genetic compositions,
experimental conditions, and biological markers (Jaworski et al., 2010). Regardless, these
models will continue to play an important role in the biological and mechanistic
understanding of AD in the coming years. The evidence presented here suggests that the
development of animal models underlying epigenetic mechanisms may be most successful in
improving our understanding of sporadic AD.
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Recent findings suggest that proliferating cells in the dentate gyrus of AD brains do
not become mature neurons, nor do they migrate into synaptic networks (Li et al., 2008).
Some believe that this represents a protective mechanism, the brain’s attempt to maintain
healthy networks by not integrating potentially immature or damaged neurons, while others
suspect this may be an effect induced by medications older patients receive before death (Li
et al., 2008). Perry et al. (2012) more recently confirmed these implications, adding that
neurogenic abnormalities in AD would differ across the stages of disease progression.
Despite these findings, however, in AD brains, elevated expression of neurogenic marker
proteins, including DCX, PSA-NCAM, and NeuroD, were found in the hippocampal regions
of the SGZ; this suggests higher levels of neurogenesis occurring in disease cases. To
reconcile the findings of increased presence of neurogenic markers yet decreased levels of
proliferation in the same regions, Li et al. (2008) suggest that while there is an increase in
cell birth, these cells fail to reach maturation and integration into pre-existing circuitry.
Because neurogenesis within the dentate gyrus plays a pivotal role in the maintenance of
cognitive networks and synaptic plasticity, the functional consequences for impaired
neurogenesis these regions would include deficits in learning and memory, common
hallmarks of AD.
The observed alterations in neurogenesis for patients experiencing symptoms of
epilepsy, stroke, and AD suggest that neurogenesis responds to these conditions
(Fitzsimmons et al., 2014); it cannot be ruled out, however, that neurogenesis and its
dysfunction may also contribute to the persistence and progression of these diseases. As
previously stated, the process of adult neurogenesis is extensively regulated. Some of these
regulators include environmental and hormonal factors, such as pharmacological agents,
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growth factors, exercise, and stress (Fitzsimmons et al., 2014). Observations by Covic et al.
(2010) propose that epigenetic mechanisms exist as sensors of environmental changes and
induce small alterations of adult hippocampal neurogenesis. In animal models, spatial
exploration and exercise have been linked to methylation activity in the dentate gyrus;
environmental enrichment is a well-known stimulus of hippocampal neurogenesis and
reinforces the philosophy that exercise and mental activity reduce neuropathological risk.
The overlap in neurogenesis-impacting events and those which predispose an
individual for AD draws a link between external factors and neural dysregulation, the crux of
epigenetic research. Whether dysfunctional neurogenesis is a product of AD progression or,
rather, a contributor to other proteinopathies has yet to be completely resolved. It is also
possible that these options are not mutually exclusive, that the epigenetic mechanisms
governing neurogenesis are impaired with the start of AD pathology. In essence,
biomechanical alterations as a result of AD might influence neurogenic processes, and
subsequently impacted neurogenesis processes can feed into disease pathology. These
damages to neurogenesis result in defective and unsustainable NSCs, which fail to migrate
and blend with pre-existing neural networks, leading to an extensive loss of neurons and
subsequent deficits in learning and memory behaviors. Furthermore, this cognitive decline is
a notable phenotypic hallmark of AD pathology. In the next section, I will explore the
epigenetic mechanisms by which neurogenesis is regulated and suggest possible regions by
which epigenetic alterations in AD pathology may be contributing to deficits in neurogenesis.
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Section VI. Visualizing Neurogenesis in the Epigenome
Neurogenesis is a complex process, composed of carefully orchestrated events under
considerable regulation. Epigenetic mechanisms exercise temporal and spatial control of
gene expression to construct networks of organization for cell birth, differentiation, and
migration. Many of these mechanisms interpret extracellular and environmental cues, which
can induce intrinsic neurogenesis processes. Given the prominent neurogenesis niche in the
dentate gyrus, the role of stem cells in disease rescue and repair, and the role of the
hippocampus in cognition and its dysfunction, it is reasonable to expect great developments
in the research of neurogenesis related to AD pathology and the epigenetic mechanisms
pertinent to its etiology. Understanding these intersecting biological systems will advance the
knowledge not only of the processes behind disease advancement but of the prospect for
regeneration and relevant therapeutic and preventative measures in the AD brain.
The diversity of cellular phenotypes can be attributed, in large part, to epigenetic
control of gene expression; this mechanistic control has been critically linked to cellular
differentiation (Christensen et al., 2009). The large majority of cells in a given organism
share identical DNA sequences; however, detailed epigenetic modulators determine cell
types, gene expression profiles, and characteristic phenotypes. In both embryonic and adult
neurogenesis, the birth of new neurons can be viewed through the lens of a classic stem cell
differentiation process. In this perspective, extracellular environmental cues are read by
epigenetic mechanisms; the interpretation of these cues allows for biological processes which
precisely determine the spatial and temporal expression of regulators in neural stem cells
(NSCs) in their proliferation, differentiation, maturation, and migration (Yao & Jin, 2014).
During neurogenic processes, epigenetic modulations underlie the accessibility to DNA and
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histone proteins in critical genes, shaping the larger transcriptome. These intrinsic players are
highly influential in adult neurogenesis in the SVZ and SGZ and are highly conserved from
embryonic neurogenesis. Nevertheless, the impact of extracellular elements, the neurogenic
niche, and pathology-induced alterations to the environment cannot be ignored (Lledo et al.,
2006; Ming & Song, 2011).
Unpredictable alterations to the epigenome and environment can cause normal DNA
methylation or histone acetylation processes to go awry; these changes can induce alterations
at a transcriptional level, invoking genes involved in basic processes, like neurogenesis. In
the past decade, many epigenetic regulatory mechanisms have been associated with the
timing and differentiation of neural stem cell lineages. These mechanisms include cell cycle
regulators, transcription factors, signal transducing morphogens, growth factors,
neurotrophins, and hormones (Lledo et al., 2006; Yao & Jin, 2014). These same mechanisms
have been linked to overall dysfunction and the pathogenesis of neurodegenerative disorders,
including AD, Parkinson’s Disease, schizophrenia, and autism spectrum disorders (Kauwe &
Sawamoto, 2009; Taoufik et al., 2018). The host of overlapping epigenetic mechanisms
linked both to neurogenic processes and the development and manifestation of AD imply
interactions between the two; these epigenetic coincidences join the geographic conjunction
of relevant neuroanatomical regions for AD and neurogenesis. Understanding dynamic
changes to neurogenesis across the neural epigenomic landscape over time allows for
improved identification to the onset of complex diseases, like AD.
There are many questions yet to be answered in the sphere of neurogenesis. In
particular, a topic of great experimental interest has been to examine the location specificity
of neuron production, which is limited to the dentate gyrus and the olfactory bulb. While
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cells divide in many other areas of the brain, only these two regions give rise to functioning
new neurons (Gage & Temple, 2013). The specificity of these processes appeals to an
evolutionary biologist perspective, which posits that the ability to re-encode, strengthen, and
efficiently retrieve memories acts as an adaptation benefit for humans. In a molecular sense,
the birth of new neurons can occur selectively in these locations because the environment
mechanistically suits and stimulates neurogenesis. As an environmentally-sensitive and
epigenetically-moderated process, neurogenesis can be linked to AD through geographic and
functional overlap within the hippocampus. As previously mentioned, engagement with
stimuli and the macroscopic environment, induces a proliferation of cells in the hippocampus
of mouse models, including the adult dentate gyrus; experiences, learning, and acquiring
information about the environment have an impact on survival, and, thus, their encoding as
memories suits a biological survival advantage to adapt and learn about one’s surroundings.
The emphasis of neurogenesis in AD is the result not only of shared neuroanatomical locality
(i.e. the hippocampus), but neurogenesis illustrates the epigenetic property of geneenvironment interactions, which are increasingly pertinent to growing AD research.
In response to demyelination, such as in cases of multiple sclerosis, Jablonska et al.
(2014) show changes in cell differentiation patterns. With a change in the microenvironment,
induced by the stripping of myelin in the corpus callosum, neuroblast cells began a
coordinated effort of forming oligodendrocytes, the producers of myelin in the central
nervous system. These results demonstrate how the adult brain utilizes neurogenesis
processes to compensate and recover from damage. Recent research by Ming and Song
(2011) highlights the importance of the microenvironment within neurogenic niches. They
show that, in addition to fate determination and cell differentiation, the environmental
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composition and cues contribute to triggering “self-renewal, proliferation, migration, and
maturation” processes in these regions. Little is currently known regarding these
mechanisms, but the conclusions efforts currently underway imply that these regulations are
conserved from embryonic development through adulthood. These self-renewal mechanisms,
however, are not seen in AD brains, suggesting a dysfunction in neurogenesis and the
potential failure of these processes to sense environmental dysfunction, as it would in another
neurodegenerative or neuropsychiatric condition.
During cortical development, neural stem cells generate the layers of cortex in a
precise, inside-out order along a controlled timeline (Yoon et al., 2018). The earliest-born
neurons form deep layers of the cortex, while younger cells form the upper layers. Histone
methylation has been shown to be an important regulatory mechanism over the correct
proportions of inner and outer layers of neurons (Yoon et al., 2018). The critical nature of
methylation in corticogenesis has been modeled in knockout experiments in mice. As
mentioned, microRNAs often act as fine-tuning mechanisms of gene expression, acting by
repressing or inducing mRNA in neural cells; however, miRNAs can also act directly with
transcription factors to guide the migration of new neurons. The modulation of signaling
molecules in cell proliferation and differentiation implies a crucial role for miRNAs during
neurogenesis. Though the complexities of the neurogenesis process are still elusive, the
differentiation mechanism is regulated by a number of neurotrophic factors, highlighting
miRNAs as an important element to the rise of new cells and their diversity.
Because neurogenesis is regulated by a host of epigenetic mechanisms, it stands to
reason that restoration of neurogenic properties in AD pathology be conducted through
epigenetics, as well. The coming years promise novel therapeutic interventions for combating
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the disease, alongside other neurodegenerative disorders. In preclinical studies, a number of
epigenetic-based therapies have shown to alleviate cognitive impairments by promoting and
sustaining neurogenesis (Li et al., 2008). A recent study in transgenic mice carrying the
human APOE ε4 allele showed that, after environmental enrichment, there was a marked
apoptosis of neural progenitor cells (Lazarov & Marr, 2010; Levi & Michaelson, 2007).
These results imply that part of the mechanism by which the ε4 allele alters an individual’s
susceptibility to AD involves a compromised neurogenesis process.

Figure 7. A chromosomal
ideogram displaying
significant loci implicated in
neurogenic processes,
represented by purple dots.
(Cui et al., 2012;
Fitzsimmons et al., 2014;
Kaneko & Sawamoto, 2009;
Schouten et al., 2012; Yao
& Jin, 2014).

Figure 6 and Figure 7 allow for a controlled model of potential epigenetic targets in
neurogenesis-affirmed regions of the AD genome. Those epigenetic candidate regions of AD
patient research indicate several regions of overlap with genetic regions moderating
neurogenesis. This intersection presents a starting block upon which future researcher teams
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might launch new epigenetic studies. Using the NCBI’s Genome Data Viewer, I have
determined and compiled nine unique genetic loci of significance in the AD epigenome
which are heavily implicated in neurogenic processes (Fig. 8, Table 2).

Figure 8. A chromosomal ideogram highlighting regions of the genome that are epigenetically
altered in AD pathology (green) and loci associated with neurogenic processes (purple); genetic
loci which appear in both systems are noted in yellow.
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Table 2. Regional distribution of authenticated genetic loci implicated in neurogenesis which
are epigenetically altered in AD pathology.
Gene

Locus

MIR34

Chromosome 1 (9151668-9151777)

MIR137

Chromosome 1 (98046070-98046171)

MEF2C

Chromosome 5 (88699654 - 88922692)

CLU

Chromosome 8 (27596917-27615031)

Sirt1

Chromosome 10 (67884669-67918390)

BACE1

Chromosome 11 (117285686-117316256)

ADAM10

Chromosome 15 (58595204-58749978)

APOE

Chromosome 19 (44905749-44909395)

MIR125

Chromosome 19 (51693254-51693339)

Given the inherently interdisciplinary nature of the search for etiological information on
neurodegenerative disorders, neurogenesis ought to pose a significant interest to geneticists
and neuroscientists alike. Furthermore, because deficits in neurogenesis are hypothesized to
occur early in the initial development of AD, a functional understanding might also improve
disease outcomes due to earlier diagnosis and therapeutic intervention.
These results fall in line with what is known about the missing heritability of AD
after accounting for significant SNPs found in GWAS studies. Ridge et al. (2013) concluded
that, outside of major SNPs, chromosomes 1, 4, 5, and 17 are responsible for the most
phenotypic variance. These distributions show potential candidates for explaining heritable
hallmarks of disease pathology, including several within chromosomes 1 and 5. Because
epigenetic mechanisms are altered in AD brains and neurogenesis is regulated by epigenetic
modulators, research into the proliferation, differentiation, and maturation of neural stem
cells poses a promising target for better understanding the genetic architecture of
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neurodegeneration. The continuing advancement of high-throughput sequencing and
genome/epigenome editing technologies promises to be a considerable aid in the process of
untangling the details of epigenetic regulatory mechanisms, including their impact on
neurogenesis. Coinciding developing technologies with longitudinal clinical studies should
be of particular interest to those invested in the eradication of neurodegenerative disorders.
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Section VII. Conclusion
Analogous to GWAS research, the new generation of EWAS publications has
produced a reliable dataset for regions of epigenetic alterations linked to complex traits and
disorders. Moving forward, the next steps for epigenomic studies will be to hone in on
promising targets for reversing damage and promoting sustainable regulation, several of
which have been presented here. In the context of AD, this thesis has presented an attractive
new pathological feature moderated by epigenetic markers. It is hoped that this intersection,
embodied by neurogenesis, might lead to critical new discoveries and research ventures as
epigenomic studies become less expensive and more accessible. These investigations reflect
an integral vista point to understand the epigenetic dysfunction mechanisms that hijack the
normal aging process into neurodegenerative disorders.
The inflection point in epigenetic research today provides the ability to visualize and
contextualize neurogenesis deficits and alterations that occur in AD pathology. Despite the
established role of epigenetic mechanisms in neurogenic processes, these neurological and
genetic disciplines have largely been applied separately to AD research. Their intersection
represents an evidence-based strategy for the two-part quest to better diagnose and recognize
complex disorders, as well as apply these findings to a treatment perspective. As such,
epigenetics and neurogenesis will continue to serve as areas of interest in the growing
research into neurodegenerative disorders. As the body of research grows to accept AD as a
disorder which falls under the control of epigenetic mechanisms, the next logical steps in
recovering missing heritability will include a focus on potential biological processes that
contribute to pathology through such epigenetic pathways. The inclusion of impaired
neurogenesis as a hallmark for this disorder is of paramount importance in progressing this
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research. Alternative targets, like neurogenesis, contribute to an improving framework for
complex age-related disorders. Furthermore, in the case of AD, these targets offer
clarification to pre-existing molecular markers for diseases; for example, recent studies have
linked neurogenic processes with the development of AD proteinopathies.
Not only is there a substantial body of research recommending the investigation of
neurogenesis as an epigenetic moderator for AD risk, but, due to the plasticity of the
epigenome, this modulation also serves as an attractive candidate for therapeutic intervention
for complex diseases. These interventions can utilize the things which naturally promote
neurogenesis, such as physical activity and engaging with the environment. Longitudinal
studies suggest that regular cognitive activity and exercise reduce the risk of AD and delay
the onset of dementia (Covic et al., 2010; Rodriguez & Verkhratsky, 2011). In a recent study
conducted in a transgenic AD mouse model, after a 6-month period of exposure to
environmental enrichment, researchers observed both an increased neurogenesis rate and a
recovery to normal values of neurogenesis observed in age-matched controls (Rodriguez &
Verkhratsky, 2011). The regulation of endogenous neurogenesis promises to be a major
target in the development of therapeutic interventions for neurodegenerative disorders,
including but not limited to AD. Future work should orient itself in the direction of this
formidable intersection and seek to distinguish the effects of epigenetically-modulated
systems on AD pathology from normal aging processes, both in animal models and human
applications. Furthermore, such experiments must be conducted in order to understand the
ways in which environmental factors bear genetic consequences on cognitive networks based
on their accumulation of exposure with age.
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APPENDIX A: Glossary of Selected Terms
Acetylation1 – A chemical process by which a hydrogen atom is replaced with an acetyl
(CH3CHO) group, through the use of acetyl co-enzyme A as a group donor
Allele2 – One of a number of variant forms of the same gene in a chromosomal locus. In an
organism, each cell contains two copies of an allele for a given genotype. Many alleles are
represented with either an upper- or lower-case letter, e.g. “A” or “a”
Chromosome2 – The highly condensed form of genetic information, containing DNA,
histone proteins, and other structural elements, located in a cell’s nucleus
CpG site2 – A location within a DNA sequence in which cytosine and guanine nucleotide
bases appear consecutively
CpG island1 – A region of the genome of one or several kilobases in length, containing a
high density of CpG dinucleotides
Declarative Memory3 – Memory that relates to facts, data, and events, broken into semantic
and episodic memory
Epigenetics2 - The study of heritable changes in genetic material that do not involve changes
in the underlying DNA sequence
Epigenomics6 – The study of genome-wide patterns of changes in chromosomes and
chromatin that lead to changes in gene expression
Epigenome-wide association study (EWAS)1 – A systematic approach to identifying a
genome-wide set of epigenetic marks for an underlying trait
Gene2 – The most basic unit of heredity. Genes represent a segment of RNA or DNA that
carries genetic information
Gene expression2 - The process by which DNA activation and inactivation is converted to
functional products, such as proteins production or cell signaling
Genome2 – The complete genetic content of an organism, often expressed in number of
nucleotide basepairs
Genotype2 – The set of alleles, situated on corresponding chromosomes, that determines a
specific trait in an individual. At any one autosomal locus, a genotype will be either
homozygous (e.g. “AA” or “aa”) or heterozygous (e.g. “Aa”)
Genome-wide association study (GWAS)1 – A method for identifying genetic variants
associated with a particular trait which surveys the entire genome for single nucleotide
polymorphisms (SNPs) between cases and controls
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Haplotype map (HAPMAP)5 – A haplotype map (HAPMAP) is a catalog of common
genetic variants via SNPs. The International HapMap Project seeks to describe patterns of
human genetic variation within health and disease
Hippocampus3 – the cortical structure located in the medial region of the temporal lobe;
declarative memories, among many other functions, are encoded by the hippocampus,
entorhinal cortex, and perirhinal cortex
Histone2 - The functional protein that acts as a spool for DNA to wrap around in the process
of condensing genetic information into chromosomes. The DNA-histone complex consists of
146 dinucleotide basepairs of dsDNA wrapped around eight histone proteins; this is called a
nucleosome
Methylation2 - The addition of a methyl (CH3) group
Neural stem cells (NSCs)4 – These self-renewing, multipotent stem cells can generate both
new neurons and glial cells in the nervous system
Neurogenesis4 – The process of new neuron birth, through NSC activation, proliferation,
differentiation and fate specification, migration, and integration into existing circuitry.
Non-coding RNA2 – The RNA molecules which function to regulate gene expression at the
transcriptional and post-transcriptional level. Epigenetically related ncRNAs include
miRNAs, siRNAs, piRNAs, and lncRNAs
SNP2 – A single nucleotide polymorphism or instance of variation between chromosomes by
a single base pair
1. National Institutes of Health. National Human Genome Research Institute. “Talking Glossary of
Genetic Terms.” Retrieved December 6, 2018, from https://www.genome.gov/glossary/
2. Genetic Science Learning Center. (2013, July 15) Epigenetics. Retrieved December 07, 2018,
from https://learn.genetics.utah.edu/content/epigenetics/
3. Hall, K., Curtin, A., Rutherford, V. (2013) Networks of Mind: Learning, Culture, Neuroscience:
1st Edition., New York, New York: Routledge.
4. Toni, N., & Schinder, A. F. (2016). Maturation and Functional Integration of New Granule Cells
into the Adult Hippocampus. Cold Spring Harbor perspectives in biology, 8(1), a018903.
doi:10.1101/cshperspect.a018903
5. Thorisson, G. A., Smith, A. V., Krishnan, L., & Stein, L. D. (2005). The International HapMap
Project Web site. Genome research, 15(11), 1592-3.
6. Klein, H.U., Bennett, D.A. & De Jager, P.L. (2016) The epigenome in Alzheimer’s disease:
current state and approaches for a new path to gene discovery and understanding disease
mechanism.Acta Neuropathol. 132: 503. https://doi.org/10.1007/s00401-016-1612-7
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APPENDIX B: Table of AD Loci Gathered from GWAS
Gene

Chromosome Function

Risk /
Frequency

PSEN 2

1q31-q42

Synaptic plasticity; amyloid-β
production; 𝛄-secretase activity

CR1

1q32

Complement activation; amyloid-β
clearance

Low /
Common

Neural development; methylation
MTHFR

1p36.22

Low /
Common

Processing of peptide precursors

Low /
Common

Membrane channel permeability

Low /
Common

Synaptic vesicle endocytosis;
cytoskeletal interactions; APP
trafficking

Low /
Common

Inflammatory response

Low /
Common

Mediates chemotaxis

Low /
Common

Mineral transport; filtration and
removal of organic material

Low /
Common

Inflammatory response

Low /
Common

Inflammatory response

Moderate /
Rare

Immune function; histocompatibility

Low /
Common

ECE1

1p36.12

CHRNB2

1q21.3

BIN1

2q14.3

IL1A, IL1B

2q14.1

CCR2

3p21.31

TF

3q22.1

CXCL8

4q13.3

Very High /
Rare

TREM2

6p21.1

HLA-DRBS
and DRB1

6p21.3

CD2AP

6p12

Cytokinesis; cytoskeletal interactions;
receptor-mediated endocytosis

Low /
Common

6p24.2

Neural precursor; signal transduction;
cell attachment and migration

Low /
Common

NEDD9
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Unknown

Low /
Common

6p21.33

Cell proliferation, differentiation,
apoptosis; lipid metabolism

Low /
Common

EPHA1

7q34

Neural development; immune function;
synapse development

Low /
Common

NME8

7p14.1

Ciliary function; neural cell
proliferation

Low /
Common

PTK2B

8p21.1

Calcium homeostasis; MAP kinase
signaling

Low /
Common

CLU

8p21-p12

Chaperone protein; complement
regulation; synapse maintenance

Low /
Common

Maturation of Th2 cells
IL33

9p24.1

Low /
Common

Programmed cell death

Low /
Common

Mitochondrial DNA replication and
repair

Moderate /
Common

Cholesterol and lipid metabolism

Low /
Common

APP processing

Low /
Common

mRNA editing; pre-mRNA splicing

Low /
Common

Signal transduction; immune function

Low /
Common

Clathrin-mediated endocytosis

PGBD1
TNF

6p22.1

DAPK1

9q21.33

TFAM

10q21.1

CH25H

10q23.31

CALHM1

10q24.33

CELF1

11p11

MS4A4E

11q12.2

PICALM

11q14

Low /
Common

SORL1

Endocytosis; APOE receptor binding;
11q23.2-q24.2 APP processing

Low /
Common

Signal transmission

Low /
Common

GAB2

11q14.1
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PSEN 1

14q24.3

FERMT2

14q22.1

GWA

14q32.13

MEF2A

5q14.3

ADAM10

15q22

MAPT

17q21.31

THRA

17q21.1

GRN

17q21.31

APOE

19q13.2

CD33

19q13.3

ABCA7

19p13.3

LDLR

Intracellular signalling; amyloid-β
production; 𝛄-secretase activity

Very High /
Rare

Cell–cell adhesion; angiogenesis

Low /
Common

Neurite branching; neurite elongation;
neuronal migration

Low /
Common

Myogenesis; synapse formation

Low /
Common

Hippocampal neurogenesis; cell
adhesion

Low /
Common

Creation of various mRNA species

Low /
Common

Thyroid hormone receptor

Low /
Common

Cell growth

Low /
Common

Synaptic vesicle endocytosis
cytoskeletal interactions; lipid transport

High /
Uncommon

Cell signalling; endocytosis

Low /
Common

Phagocytosis; lipid homeostasis

Low /
Common

Protein degradation

Low /
Common

Cell migration and adhesion

Low /
Common

Inflammatory response

Low /
Common

Channel formation

Low /
Common

Cell membrane dynamics

Low /
Common

19p13.2

BCAM

19q13.32

NECTIN2

19q13.32

TOMM40

19q13.32

EXOC3L2

19q13.32
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ENTPD6
CST3
PRNP

64

Mediation of nucleotidases (NTPases)

Low /
Common

Inhibition of cysteine proteinases

Low /
Common

Aggregate mediator

Low /
Common
Very High /
Rare
Low /
Common

20p11.21
20p11.21
20p13

APP

21q21.3

Neuron development; synapse
formation and repair; amyloid-β
production

OTC

Xp11.4

Enzyme encoding of mitochondrial
matrix

